Insider Trading & Ownership of Michael J. Higgins

Location
Cambridge, MA
Summary
The estimated net worth of Michael J. Higgins is at least $84,535 dollars as of 27 Jun 2025. Michael J. Higgins is the Director of Cyclerion Therapeutics, Inc. and owns shares of Cyclerion Therapeutics, Inc. (CYCN) stock worth about $84.5K.
Signature
/s/ Josh Mandel-Brehm, as Attorney-in-Fact
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow Michael J. Higgins and return when a new Insider Trading filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.

Sign up to save research and follow filings

Quick Takeaways

  • Michael J. Higgins has 5 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $84,535.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: Cyclerion Therapeutics, Inc. ($84,535).
  • Past-year value change for that position: .

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Source Evidence

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of Michael J. Higgins

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
CYCN Cyclerion Therapeutics, Inc. Director $84,535 25 Mar 2025
CAMP Camp4 Therapeutics Corp Director 25 Jun 2025
GNCA GENOCEA BIOSCIENCES, INC. Director 01 Jul 2021
PULM Pulmatrix, Inc. Director 26 Jan 2023
VYGR Voyager Therapeutics, Inc. Director 03 Jun 2025

Insider Transactions Reported by Michael J. Higgins:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .